Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals. While the company raised guidance and is optimistic about growth, financial metrics reveal increasing losses and operating expenses. The Q&A highlighted positive developments in in-network expansion and prescription growth, but also noted management's lack of detailed guidance on key strategic initiatives. The overall sentiment is balanced by the bullish outlook and ongoing investments, suggesting a neutral stock price movement in the short term.
Key Financial Performance
Revenue $19.4 million in the first quarter, an increase of 52% compared to the prior year period. Revenue growth was driven by a 51% year-over-year increase in prescriptions, reflecting market share gains with existing customers and activation of new accounts.
Gross Margin 45.7% in the first quarter compared to 32.9% in the prior year period. The continued expansion in gross margin was driven by the attractive unit economics inherent in Kestra's rental model, a higher revenue per fit from more in-network patients, and a lower cost per fit, driven by volume leverage and cost improvement projects.
Cost per Fit Decreased approximately 20% compared to the prior year period. This reduction was attributed to volume leverage and cost improvement projects.
Adjusted Revenue per Fit Increased approximately 20% compared to the prior year period. This was due to a higher mix of in-network patients.
Conversion Rate Approximately 47% in the first quarter compared to an adjusted conversion rate of approximately 40% in the prior year period. The higher conversion rate reflected improvements in prescription fill rate, bill rate, and collections performance.
GAAP Operating Expenses $37.7 million in the first quarter, including $2.9 million of nonrecurring new public company costs. This is compared to $22.6 million in the prior year period. The increase was primarily attributable to growth investments in commercial and revenue cycle resources.
GAAP Net Loss $25.8 million in the first quarter compared to a GAAP net loss of $20.3 million in the prior year period. The increase in net loss was due to higher operating expenses.
Adjusted EBITDA Loss $19.4 million in the first quarter compared to an adjusted EBITDA loss of $15.7 million in the prior year period. The increase was due to growth investments in commercial and revenue cycle resources.
Cash and Cash Equivalents $201.2 million as of July 31, 2025. The company expects this balance to be sufficient to reach cash flow breakeven and profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ASSURE system: Tracks heart rate trends, allows patients to trigger ECG recordings, and provides critical insights for identifying undiagnosed arrhythmias. It also delivers life-saving therapy during cardiac arrest and ensures rapid emergency support.
Prescription growth: 4,200 prescriptions for the ASSURE system in Q1 FY26, a 51% year-over-year increase.
Revenue growth: Revenue grew 52% year-over-year to $19.4 million in Q1 FY26.
Market expansion: WCD therapy remains underutilized, reaching only 14% of the eligible U.S. patient population. Kestra aims to expand this market.
Gross margin improvement: Gross margin increased to 45.7% in Q1 FY26 from 32.9% in the prior year period, marking the seventh consecutive quarter of gross margin expansion.
Revenue cycle management: In-network fittings increased from 70% to 80%, improving efficiency and key RCM metrics.
Fleet scalability: Kestra's lease business model supports scalability with devices capable of approximately 3 patient wears per year.
Sales organization expansion: Expanded sales territories and introduced a clinical specialist role to penetrate existing accounts and target new prescribers.
Clinical evidence development: Concluded enrollment in FDA post-approval study and achieved a late breaker presentation at the American Heart Association Scientific Sessions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Expansion Challenges: Despite the growing market for wearable cardioverter defibrillators (WCDs), the therapy remains underutilized, reaching only 14% of the eligible U.S. patient population. This indicates a significant challenge in expanding market penetration and adoption.
Revenue Cycle Management (RCM) Complexity: Kestra faces challenges in managing over 3,000 payers in the U.S., which complicates bringing more payers in-network. This impacts efficiency and key RCM metrics, such as prior authorization and collections performance.
Operational Costs and Losses: The company reported a GAAP net loss of $25.8 million in the first quarter, an increase from the prior year's $20.3 million. Operating expenses also rose due to growth investments, which could strain financial resources.
Competitive Pressures: The incumbent competitor in the WCD market is actively investing in studies and market expansion, posing a threat to Kestra's market share and growth.
Regulatory and Clinical Evidence Requirements: Kestra is heavily reliant on clinical studies to validate the safety and efficacy of its ASSURE system. Delays or unfavorable outcomes in these studies could impact market acceptance and regulatory compliance.
Supply Chain and Fleet Management: Kestra's lease business model requires substantial investment in its fleet of devices. While the current asset pool supports near-term objectives, scaling operations could require additional capital and efficient fleet management.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Gross Margin Expansion: Kestra expects continued gross margin expansion in FY '26 and remains confident in achieving 70%+ gross margins over the next few years.
Revenue Growth: Kestra has updated its fiscal year 2026 revenue guidance to $88 million, reflecting a 47% increase compared to fiscal year 2025. This growth is underpinned by strong growth in prescriptions, market share gains, and activation of new accounts.
Revenue Per Fit: Revenue per fit is expected to continue benefiting from a higher mix of in-network patients and improvements in revenue cycle management capabilities.
Market Expansion: The WCD market is expected to expand into a multibillion-dollar market over the coming years, driven by increased utilization and evidence of higher-than-expected sudden cardiac arrest risk in certain patient populations.
Clinical Evidence and FDA Study: Kestra has concluded enrollment in its FDA post-approval study, which is expected to be the largest study ever published in the WCD category. Results will be presented at the American Heart Association Scientific Sessions in November.
Cash Flow and Profitability: Kestra expects its existing cash balance to be sufficient to reach cash flow breakeven and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the confidence to raise guidance early in the year and how should we think about the cadence over the year?
A:The company had a strong Q1 and is bullish about the rest of the year. They are comfortable with the guidance update but will monitor how things play out over the next quarter or two.
Q:What is being done to improve the in-network mix and its impact on gross margins?
A:The company has increased in-network patient coverage from 70% at IPO to about 80%. They are engaging with more payers, focusing on efficient territory expansion, and expect gradual revenue growth per patient as in-network contributions increase.
Q:What progress has been made in expanding into areas with greater in-network opportunities?
A:The company is adding payers in a non-linear fashion, focusing on regional payers to support high-demand territories. This strategy aims to provide insurance coverage to new reps, enabling them to compete effectively.
Q:How should we think about the quarterly flow and the impact of the raised guidance?
A:The company expects a steady increase in top-line growth throughout the year, rather than being back-end loaded, due to ongoing investments in new territory managers and operational expenses.
Q:What improvements are being seen in prescription numbers and where could the company end the year in terms of prescription share?
A:Prescription numbers are improving due to the productivity of both experienced and new reps. The company is currently annualizing at about 14% of cases and expects further growth as new reps focus on high-prescriber accounts.
Q:Are new reps focusing on converting existing accounts or expanding the market?
A:New reps are initially targeting high-prescriber accounts, while experienced reps focus on further penetrating existing accounts and opening new ones to grow the market.
Q:What does the guidance assume for the year-over-year increase in the conversion rate?
A:The guidance assumes a 2.5 to 3-point increase in the conversion rate, driven by improvements in in-network patient mix, payer additions, and investments in the RCM team.
Q:What is the company's current market share and what is the plan to achieve category leadership?
A:The company estimates its market share at around 12% and plans to achieve category leadership by expanding sales coverage, which is currently at just over 50% of the U.S. market.
Q:What is the expanded role of clinical specialists and how will it be deployed?
A:Clinical specialists will take over account management in high-performing territories, allowing sales reps to focus on cultivating new accounts. This strategy will initially target high-performing territories.
Q:What are the key aspects and expected impact of the upcoming post-approval study presentation at AHA?
A:The study includes 24,000-25,000 patients and focuses on shock success rate, inappropriate shocks, false alarm rate, and patient compliance. The results are expected to address competitive objections and highlight the ASSURE system's effectiveness.
Q:How are compliance rates evolving and what are the company's goals in this area?
A:Daily median wear time is over 23 hours, and patients tend to remain compliant throughout their prescription duration. The company prioritizes compliance to ensure therapy effectiveness.
Q:What is the cadence of OpEx investments for the rest of the year?
A:The company plans steady and measured investments, focusing on adding high-quality reps and supporting them to build a durable commercial team.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline to achieve category leadership, the exact impact of payer additions on conversion rates, and the precise cadence of OpEx investments. Additionally, while they highlighted the importance of compliance and the upcoming post-approval study, they did not provide detailed data or insights on these topics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASSURE system
Chief
Investor Relations
Kestra
Officer
President Investor
RCM
Vaseem
Vice President
WCD
afternoon
capability
care
day
driver
evidence
expansion
heart
insight
leverage
life
margin
market
mission
month
network
patient risk
payer
period
provider
recording
result
rhythm
risk arrest
sale
statement
study
territory
therapy
today
volume
KMTS Transcript
Kestra Medical Technologies, Ltd. (KMTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Unknown3-17
The earnings call presents a mixed sentiment. While there is optimism with increased revenue guidance, gross margin expansion, and market growth, there are also concerns. The widening net loss and adjusted EBITDA loss, along with management's reluctance to provide specific guidance, could dampen investor sentiment. Additionally, the stock's reaction to strong gross margins and prescription growth suggests possible market skepticism. The Q&A insights highlight the company's strategic initiatives and market opportunities, but the financial uncertainties and competitive landscape may balance the positive aspects, resulting in a neutral outlook for the stock price.
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript
Positive12-11
The earnings call reveals strong revenue growth, market expansion, and a strategic focus on innovation. Despite increased losses, cash reserves are robust. The Q&A highlights sustainable growth strategies and positive market reaction to clinical data. The company's guidance and strategic plans suggest a positive outlook, with expected gross margin expansion and increased prescription volumes. While there are uncertainties regarding guideline changes, the overall sentiment is positive, driven by strong financial metrics and optimistic guidance, likely leading to a stock price increase in the short term.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
